Changes in total foveal thickness, visual acuity, and M-CHARTS score after initiating intravitreal ranibizumab therapy for macular edema associated with branch retinal vein occlusion.

(A)–(C), All included eyes (n = 32 eyes). (D)–(F), Eyes with no macular edema at 12 months (n = 23 eyes). (G)–(I), Eyes with an injection-free period of at least 6 months at 12 months (n = 13 eyes). Visual acuity was converted to the logarithm of the minimum angle of resolution (logMAR) for all analyses. The M-CHARTS score was the higher among the vertical and horizontal scores. *indicates P P < 0.05 compared to baseline values. M = month(s). Error bars represent 95% confidence intervals.